Sign up to The Irish Times Archive (1859 - 2008)My Account »
Sat 11 Nov 2009Elan updates Tysabri label to warn of risks of brain disease
ELAN HAS updated the label on its breakthrough multiple sclerosis (MS) drug Tysabri to reflect the increased risk of patients contracting a serious brain disease if they are on the drug for more than two years.
The company announced last night that, effective immediately, it was updating the label on the drug in the US market following consultation with the US regulator, the Food and Drug Administration (FDA).
Choose a Subscription type - required
